利用基因突变对滤泡性淋巴瘤患者进行分层的前景与挑战
滤泡性淋巴瘤(FL)临床与分子高度异质,约20%患者早期进展且总生存期短,目前治疗未依据个体风险或疾病生物学指导。近期研究显示基因突变可作预后和/或预测生物标志物,尤其整合入复合风险模型时;但转化为常规临床实践前仍面临多重挑战。本文综述「临床遗传学」风险模型的开发与验证,并提出众包策略以加速模型开发、验证、优化与选择。
要点
- 约20%的滤泡性淋巴瘤患者出现早期疾病进展且总生存期短。
- 基因突变可作为预后和/或预测生物标志物,尤其整合入复合风险模型时。
- 作者提出众包策略以加速风险模型的开发、验证、优化与选择。
核心结论
- 若希望从经验性选择治疗转向基于风险、生物学指导的滤泡性淋巴瘤治疗,需要协作与协调的新时代。
研究设计与样本
- 综述,聚焦适用于滤泡性淋巴瘤及其他癌症的「临床遗传学」风险模型开发与验证。
主要发现
- 多数滤泡性淋巴瘤患者经当前治疗可获得持久缓解且总生存期极佳。
- 约20%的滤泡性淋巴瘤患者出现早期疾病进展且总生存期短。
- 目前治疗未依据个体风险或疾病生物学指导。
- 近期研究显示基因突变可作为预后和/或预测生物标志物,尤其整合入复合风险模型时。
- 滤泡性淋巴瘤患者数量及开展足够把握度试验的资源有限。
临床怎么用
- 作者提出众包努力可加速风险模型的开发、验证、优化与选择。
- 原文未据此给出具体临床推荐。
局限性
- 将基因突变研究结果转化为常规临床实践前仍面临多重挑战。
- 滤泡性淋巴瘤患者数量及开展足够把握度试验的资源有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) is a clinically and molecularly highly heterogeneous disease. Most patients achieve long-lasting remissions and have excellent overall survival (OS) with current treatment. However, ∼20% of patients have early progression of disease and short OS. At present, therapies are not guided by individual risk or disease biology. Reliable tools for patient stratification are urgently needed to avoid overtreatment of low-risk patients and to prioritize alternative approaches in high-risk patients. A rapidly expanding repertoire of promising therapeutic options is available for clinical evaluation; however, the numbers of patients with FL and the resources to conduct adequately powered trials are limited. Recent studies have shown that gene mutations can serve as prognostic and/or predictive biomarkers, in particular when integrated into composite risk models. Before translating these findings into routine clinical practice, however, several challenges loom. We review aspects of "clinicogenetic" risk model development and validation that apply to FL and more generally to other cancers. Finally, we propose a crowdsourcing effort that could expedite the development, validation, refinement, and selection of risk models. A new era of collaboration and harmonization is required if we hope to transition from empiric selection of therapeutics to risk-based, biology-guided treatment of patients with FL.
引用
- Weigert O, Weinstock DM. The promises and challenges of using gene mutations for patient stratification in follicular lymphoma. Blood. 2017. PMID: 28784599. doi:10.1182/blood-2017-07-737353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。